Advocacy Campaigns

CCA works to advocate for the IBD community in a range of ways:

  • Lobbying governments for funding
  • Providing submissions about health policy
  • Raising consumer needs to researchers and industry
  • Awareness campaigns

Current advocacy campaigns

nurse with mask

Help improve the quality of life for regional Australians living with chronic inflammatory conditions

Crohn’s & Colitis Australia has been working in partnership with eight other organisations to seek the support of government for A Proposal to Fund Nurses in Regional Centres to Support People Living with Chronic Inflammatory Conditions. Learn about how you can help secure support for this proposal for an election commitment from politicians and candidates during the 2022 Federal election.

Review of the National Medicines Policy

Closed October 2021.

Have your say on PBD listings for IBD Medications – March 2022

The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on an ulcerative colitis medication.

If you have experience taking IBD medications you may like to provide feedback on what difference it has made to your life by email to [email protected].

CCA will then forward your comments grouped with those of others to PBAC.

The closing date for comments to CCA is May 25th 2022.

Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listingOZANIMOD
Capsule 920 micrograms
Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms
Zeposia®
Celgene Pty Limited
Ulcerative ColitisTo request a General Schedule Authority Required (Written) listing for the
treatment of moderate to severe ulcerative colitis.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Adalimumab

All PBS-listed forms

Yuflyma®

Celltrion Healthcare Australia Pty Ltd
Severe Crohn disease

Moderate to severe ulcerative colitis

Severe active juvenile idiopathic
arthritis

Complex refractory fistulising Crohn’s disease

Severe active rheumatoid arthritis

Severe psoriatic arthritis

Ankylosing spondylitis

Severe chronic plaque psoriasis

Moderate to severe hidradenitis
suppurativa
To request listing of adalimumab biosimilar under the
same conditions as its reference biologic.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Risanknizuman

Solution concentrate for I.V. infusion 600 mg in 10 mL
Injection 360 mg in 2.4 mL in pre-filled cartridge

Skyrizi®

AbbVie Pty Ltd
Crohn’s diseaseTo request General Schedule Authority Required (Written) listings for the treatment of severe Crohn’s disease and for complex refractory fistulising Crohn’s disease.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Upadacitinib

Tablet 15 mg
Tablet 30 mg
Tablet 45 mg

Rinvoq®

AbbVie Pty Ltd
Ulcerative colitisTo request a General Schedule Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis, in patients who are contraindicated to, or whose disease has not adequately responded to conventional therapies.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Ustekinumab

Injection 90 mg in 1 mL pre-filled syringe

Stelara®

Janssen-Cilag Pty Ltd
Severe Crohn disease

Severe chronic plaque psoriasis
To request a General Schedule Authority Required (Written) listing of a new form for the treatment of patients with Crohn’s disease and chronic plaque psoriasis.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Ustekinumab

Injection 90 mg in 1 mL pre-filled syringe
Solution concentrate for I.V. infusion 130 mg in 26 mL

Stelara®

Janssen-Cilag Pty Ltd
Ulcerative colitisTo request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listings for the treatment of moderate to severe ulcerative colitis, in patients who are contraindicated to, or whose disease has not adequately responded to conventional therapies.
Submission type
Drug Name, form(s), strength(s) and SponsorDrug Type and UseListing requested by Sponsor / Purpose of Submission
Change to PBS listing
Teduglutide
 
5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes]
 
Revestive® Takeda Pharmaceuticals Australia Pty. Ltd
 
(Sub-committee report
DUSC Analysis)
Type III Short Bowel Syndrome with intestinal failureTo compare the predicted and actual utilisation of teduglutide for Type III Short Bowel Syndrome with intestinal failure in the first 24 months of PBS listing.